Summary: Tau PET neuroimaging could help open the door to developing new drugs to treat Alzheimer’s disease.
Source: Lund University.
Tau PET is a new and promising imaging method for Alzheimer’s disease. A case study from Lund University in Sweden now confirms that tau PET images correspond to a higher degree to actual changes in the brain. According to the researchers behind the study, this increases opportunities for developing effective drugs.
There are several different methods of producing images showing the changes in the brain associated with Alzheimer’s disease. The tau PET method reveals the presence of a protein in the brain, tau, with the help of a gamma camera and a specially selected radioactive molecule (F-AV-1451).
Tau has an important function in assisting the transport of various substances within the brain’s nerve cells. People with Alzheimer’s disease have raised levels of tau, leading to accumulation of the protein in the brain cells and gradually to cell death.
Lund University and Skåne University Hospital are among other institutions studying patients with the tau PET method for research purposes. Until now, no one has had precise knowledge of how well the new imaging method reproduces the actual changes in a brain affected by Alzheimer’s disease. The current case study, however, shows that image and reality match up well. The study has enabled researchers to compare tau PET images and brain tissue from the same person for the first time. The brain tissue came from a person who died having recently undergone examination with the new imaging method.
“Tau PET can improve diagnostics, but above all, the imaging method can be of great significance in the development of new drugs to combat Alzheimer’s disease”, explains Ruben Smith, researcher at Lund University and physician at Skåne University Hospital. He continues:
“There are new candidate drugs which aim to reduce the accumulation of tau. The imaging method opens up opportunities to investigate the development of the disease at a detailed level, and to observe how tau aggregates are affected by the drugs.”
“The person who was examined had a mutation which led to the same type of accumulation of tau in the brain as in Alzheimer’s disease. A single case study might seem insignificant, but since there are areas with a lot of tau stored and others with less tau in the same brain, it is sufficient to examine one person in order to verify whether the imaging method works”, explains Oskar Hansson, professor at Lund University and consultant at Skåne University Hospital.
Interest from the research community in imaging methods focusing on tau is strong and growing. A reliable reproduction of tau protein in the brain is considered a more relevant marker and a better diagnostic tool than competing methods which are already in use.
The researchers behind the study are now focusing on tracking aggregation of tau in the brain over time and connections with diagnostics using spinal fluid samples.
Tau PET imaging is considered interesting for other, less common, neurological diseases as well, such as frontal lobe dementia and Parkinson’s-like diagnoses such as PSP (progressive supranuclear palsy) and CBD (corticobasal degeneration).
Funding: The results are published in the journal Brain and the study was funded by the European Research Council (ERC), the Swedish Research Council, the Swedish Alzheimer’s Fund and the Swedish Brain Fund, among others.
Source: Cecelia Schubert – Lund University
Image Source: NeuroscienceNews.com image is credited to Michael Schöll.
Original Research: Full open access research for “18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers” by Ruben Smith, Andreas Puschmann, Michael Schöll, Tomas Ohlsson, John van Swieten, Michael Honer, Elisabet Englund, and Oskar Hansson in Brain. Published online June 29 2016 doi:10.1093/brain/aww163
[cbtabs][cbtab title=”MLA”]Lund University. “New Imaging Technique Opens Possibility for Alzheimer’s Drug Development.” NeuroscienceNews. NeuroscienceNews, 29 September 2016.
<https://neurosciencenews.com/neuroimaging-alzhiemers-pharmacology-5159/>.[/cbtab][cbtab title=”APA”]Lund University. (2016, September 29). New Imaging Technique Opens Possibility for Alzheimer’s Drug Development. NeuroscienceNews. Retrieved September 29, 2016 from https://neurosciencenews.com/neuroimaging-alzhiemers-pharmacology-5159/[/cbtab][cbtab title=”Chicago”]Lund University. “New Imaging Technique Opens Possibility for Alzheimer’s Drug Development.” https://neurosciencenews.com/neuroimaging-alzhiemers-pharmacology-5159/ (accessed September 29, 2016).[/cbtab][/cbtabs]
Abstract
18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
Tau positron emission tomography ligands provide the novel possibility to image tau pathology in vivo. However, little is known about how in vivo brain uptake of tau positron emission tomography ligands relates to tau aggregates observed post-mortem. We performed tau positron emission tomography imaging with 18F-AV-1451 in three patients harbouring a p.R406W mutation in the MAPT gene, encoding tau. This mutation results in 3- and 4-repeat tau aggregates similar to those in Alzheimer’s disease, and many of the mutation carriers initially suffer from memory impairment and temporal lobe atrophy. Two patients with short disease duration and isolated memory impairment exhibited 18F-AV-1451 uptake mainly in the hippocampus and adjacent temporal lobe regions, correlating with glucose hypometabolism in corresponding regions. One patient died after 26 years of disease duration with dementia and behavioural deficits. Pre-mortem, there was 18F-AV-1451 uptake in the temporal and frontal lobes, as well as in the basal ganglia, which strongly correlated with the regional extent and amount of tau pathology in post-mortem brain sections. Amyloid-β (18F-flutemetamol) positron emission tomography scans were negative in all cases, as were stainings of brain sections for amyloid. This provides strong evidence that 18F-AV-1451 positron emission tomography can be used to accurately quantify in vivo the regional distribution of hyperphosphorylated tau protein.
“18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers” by Ruben Smith, Andreas Puschmann, Michael Schöll, Tomas Ohlsson, John van Swieten, Michael Honer, Elisabet Englund, and Oskar Hansson in Brain. Published online June 29 2016 doi:10.1093/brain/aww163
